Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 9, 2021

Laurent to continue study of LAU-7b in Covid-19 patients

Laurent Pharmaceuticals has decided to continue the study of its pro-resolving drug LAU-7b without modification in the Phase II RESOLUTION study in hospitalised Covid-19 patients.

Laurent Pharmaceuticals has decided to continue the study of its pro-resolving drug LAU-7b without modification in the Phase II RESOLUTION study in hospitalised Covid-19 patients.

LAU-7b is a new oral form of fenretinide, an atypical retinoid that works on fatty acid desaturases to regulate key membrane lipids that perform key roles in inflammation and immune defence.

This development comes after the independent Data Safety Monitoring Board (DSMB) recommended continuation of the trial after it conducted a pre-scheduled safety review and mid-study interim futility analysis of unblinded efficacy data from the first 102 patients treated in the trial.

The placebo-controlled study is analysing whether LAU-7b is a safe and effective treatment option for hospitalised Covid-19 patients who are at risk of lung complications owing to age or underlying conditions or both.

It will enrol 220 subjects in hospitals across the US and provide treatment to the participants for 14 days.

To inform the trial’s primary and secondary endpoints, it will evaluate disease progression on a 7-point ordinal scale. Duration of hospitalisation and progress in the quality of life will also be evaluated.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Laurent Pharmaceuticals president and CEO Radu Pislariu said: “Because fenretinide targets the human host cell membrane lipids involved in both viral replication and immune-inflammatory responses, its activity is expected to be maintained regardless of the coronavirus variants and be complementary to virus-specific antivirals such as remdesivir.

“LAU-7b has a well-established safety profile, a convenient once-a-day oral administration, and potential for a dual antiviral and inflammation-controlling mechanism of action, which bears the promise of a treatment candidate addressing multiple key contributors to the severity of Covid-19.”

The company has also concluded enrolment in its Phase II APPLAUD study of LAU-7b to treat adult patients with Cystic Fibrosis (CF).

This placebo-controlled study is assessing the efficacy and safety of LAU-7b in CF treatment will also analyse LAU-7b’s effect on the resolution of inflammation and preservation of lung function.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU